K., Kang, Y., & Merlin, D
, adalimumab, infliximab, certolizumab, canakinumab, tocilizumab, sarilumab, and secukinumab) are monoclonal antibodies and have special targets like tumor necrosis factor (TNF)-, interleukin (IL)-6, IL-1, and IL-17 ( Although the above mentioned DMARDs have been quite successful in mitigating RA, it is still an undeniable fact that a significant proportion of patients could experience treatment failure, including nonresponse and limited efficacy ( With the deepening of research and exploration, many molecules are identified to exert important roles and bring novel insights to prevent RA
Oxidative stress, neuroinflammation, and neuronal damage all impair sleep quality even when the circadian system is functioning
Recurrence can occur, and repeat treatment is limited by radiation exposure and the risk of facial numbness
Cellular senescence research: As a telomerase activator, this compound is a primary research tool in studies of cellular senescence, replicative lifespan, and the biology of the Hayflick limit.
